UroGen Pharma Ltd.
URGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$43.09
▼ -1.22%
P/E
-21.76
Mkt Cap
$2.1B
52-Wk Range
$15.86–$50.81
52-Week Range
$15.86 - $50.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 120.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary RTGel reverse thermal gelation hydrogel technology enabling superior drug delivery and tissue retention
- Strategic partnerships with Allergan and Agenus providing development and commercialization resources
- Collaboration with MD Anderson Cancer Center enhancing clinical credibility and research capabilities
- First-mover advantage in intravesical delivery for non-muscle invasive urothelial cancers
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Strong growth ahead
UGN-102 Phase III clinical trial progression toward FDA approval for bladder and upper tract cancers
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+59.4% over 3m
Quality
Excellent
High-growth business (100% revenue growth, 91% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying URGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.28 vs -$0.27 consensus (-5.7% surprise). Revenue of $72.5M vs $63.5M expected (+14.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-5.7%
Revenue trend · last 8Q
—
+4%
+8%
+11%
+9%
+54%
+152%
+199%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$25.2M
$24.6M
$20.3M
$24.2M
$27.5M
$37.8M
$51.0M
$72.5M
Margins · last 8Q
Gross
90.9%
Operating
0.1%
Profit
-19.8%
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 6, 2026
vs Industry
How URGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related